The Risks of Alternative Funding Programs for Rare Disease Patients' Health This article explores the dangers posed by Alternative Funding Programs (AFPs), which often compel patients to use unsafe therapies not approved by the FDA.

The Risks of Alternative Funding Programs for Rare Disease Patients' Health #United_States #Washington #Gilead_Sciences #Rare_Access_Action_Project #FDA_warnings